Supporting Cell & Gene Therapy through Multimodal & Flexible Facilities

Monday 05 December 2022

Cell and gene therapies (C&GT) have unique needs in manufacturing suites that differ from those for classic product biopharmaceuticals. Facilities must be created with flexibility in mind, able to run multiple products and production types to remain viable.

In the November/December  issue of ISPE's Pharmaceutical Engineering®, DPS Group Global's Stephen Judd CEng MIChemE FIEI and William Whitford discuss types of facilities and design considerations for cell and gene therapies.

Available to read now: https://ispe.org/pharmaceutical-engineering/november-december-2022/supporting-cell-gene-therapy-through-multimodal?utm_campaign=2022%20PE&utm_content=229939845&utm_medium=social&utm_source=linkedin&hss_channel=lcp-214189